REVIEW ARTICLE

The triad of erectile dysfunction, hypogonadism and the metabolic syndrome

R. Shabsigh,1 S. Arver,2 K. S. Channer,3 I. Eardley,4 A. Fabbri,5 L. Gooren,6 A. Heufelder,7 H. Jones,8 S. Meryn,9 M. Zitzmann10

OnlineOpen: This article is available free online at www.blackwell-synergy.com

Aim: To identify the relationship of erectile dysfunction, hypogonadism and the metabolic syndrome in the context of men's health. Methods: An Expert Panel Meeting was held in December 2006 in Vienna, Austria. In addition a comprehensive literature search was conducted. Results: Men have a higher incidence of cardiovascular events than women of similar ages which has led to the belief that testosterone is a risk factor for cardiovascular disease in men. The latter hypothesis is no longer tenable. On the contrary, low testosterone levels are associated with (visceral) obesity, the metabolic syndrome, diabetes mellitus, cardiovascular disease and erectile dysfunction (ED). Testosterone therapy does not lead to an increased incidence of cardiovascular disease or events such as myocardial infarction, stroke or angina. Until recently (visceral) obesity, the metabolic syndrome, diabetes mellitus, cardiovascular disease and ED were viewed as more or less independent entities affecting the ageing male. It was not recognised that hypogonadism is a common denominator. With a more integrative approach to the health situation of middle-aged and elderly men, these conditions appear closely interrelated in their manifestations, hypothetically in their aetiology, diagnostic strategy and also their treatment. Conclusion: Improving sexual health is a portal to identify health hazards and improving men's health. Appropriate diagnosis and medical work up of men presenting with sexual symptoms may have the benefit of the diagnosing and treating other important conditions, such as obesity, diabetes, hypertension and hyperlipidaemia.

There has traditionally been a widely held belief that testosterone is a risk factor for cardiovascular disease in men. This belief was based on the observation that men have both a higher incidence of cardiovascular events and higher testosterone levels than women of similar ages. However, few, if any, recent observations support a causal relation between higher testosterone levels and heart disease (1–3). On the contrary, several studies suggest that higher testosterone levels are associated with a more favourable risk effect on the risk of cardiovascular disease (4,5). Studies of testosterone therapy have not demonstrated an increased incidence of cardiovascular disease or events such as myocardial infarction, stroke or angina (6,7). Evidence that testosterone therapy may be beneficial for men with cardiac disease is becoming stronger (8,9).

This paper will analyse the interrelationship between the metabolic syndrome, diabetes mellitus, cardiovascular disease, (visceral) obesity, erectile dysfunction (ED) and hypogonadism in (ageing) men. Until recently, they were viewed as more or less independent entities befalling the ageing male, if necessary, treated by various medical specialties. With a more integrative approach to the health situation of middle-aged and elderly men, these conditions appear closely interrelated in their manifestations, hypothetically in their aetiology, diagnostic strategy and also their treatment. This paper takes the position that (improving) sexual health is a portal to identify health hazards and improving men's health. Appropriate diagnosis and medical work up of men presenting with sexual symptoms may have the benefit of the diagnosing and treating other important conditions, such as obesity, diabetes, hypertension and hyperlipidaemia.

Review Criteria

The original premise for this review arose from an Expert Panel Meeting held in December 2006 in Vienna, Austria and sponsored by Bayer-Schering AG, Berlin, Germany. The panel discussed whether the low testosterone levels found in men with the metabolic syndrome are an essential element of the syndrome. Further, it was discussed that sexual dysfunction in middle-aged and elderly men should be viewed in the context of their general health.

Message for the Clinic

When middle-aged and elderly men seek medical advice for sexual dysfunction, their complaints should no longer be viewed as a single diagnostic/therapeutic entity. Sexual dysfunction is usually an expression of impairment of general health, not rarely the metabolic syndrome. Diagnosis and treatment should include assessment of the components of the metabolic syndrome, which are (visceral) obesity, hypertension, insulin resistance and diabetes mellitus and dyslipidaemia. Thus sexual dysfunction should be a portal to men's health.

© 2008 The Authors
Journal compilation © 2008 Blackwell Publishing Ltd Int J Clin Pract, May 2008, 62, 5, 791–798

791
The epidemic of obesity and cardiovascular disease and diabetes: the metabolic syndrome

Obesity is a condition that is reaching epidemic proportions in both the developed and the developing world (10). A preferential accumulation of intra-abdominal fat is associated with hypertension, dyslipidaemia [elevated levels of cholesterol, of triglycerides, of low-density lipoproteins (LDLs) and low levels of high-density lipoproteins (HDLs)], impaired glucose tolerance with hyperinsulinaemia, a cluster known as the ‘metabolic syndrome’ (11–13) (Table 1). There is a debate in the literature whether combining these components or conditions has an added diagnostic or prognostic value. Meanwhile, there are three main definitions of the metabolic syndrome. These definitions overlap but differ in the points of emphasis of the components (14–16). The metabolic syndrome is not an end disease by itself but its rather a pathway to disease. A clinical investigation analysing 11 prospective European cohort studies of 6156 men with a median follow-up of 8.6 years found that non-diabetic persons with the metabolic syndrome had increased risk of death of all causes as well as cardiovascular disease (17). The West of Scotland Coronary Prevention Study followed 6000 men for periods over 5 years and found that men with four or five features of the metabolic syndrome had a 3.7-fold increases in coronary heart disease events and, even more strikingly, a 24.5-fold increase in new-onset diabetes (18).

Epidemiological studies linking risk factors of cardiovascular disease to low testosterone levels

Initially cross-sectional studies but later also longitudinal studies were able to confirm that low testosterone levels and sex hormone-binding globulin (SHBG) were predictive of the metabolic syndrome, not only in obese men but also in men with a body mass index (BMI) < 25 kg/m² (19–21). The same applied to the risks of developing diabetes mellitus type 2 (22–24). The association between low testosterone/low SHBG levels and the metabolic syndrome is beyond any reasonable doubt now. The cause and effect relation remains, however, a subject of further study. The following will examine the relationship between testosterone on the one hand and the metabolic syndrome in greater detail. It is becoming clear that the relationship is in fact a two way street: low levels of testosterone predispose to (visceral) adiposity and (visceral) adiposity suppresses the production of testosterone.

The relationship between hypogonadism and insulin resistance and diabetes mellitus

Cross-sectional epidemiological studies have reported a direct correlation between plasma testosterone and insulin sensitivity, and low testosterone levels are associated with an increased risk of type 2 diabetes mellitus in men (21,24–26), for review: (27,28). A study in untreated hypogonadal Klinefelter patients using the hyperinsulinaemic euglycaemic clamp technique found hyperinsulinaemia and insulin resistance in these patients (29).

Table 1 Definitions of the metabolic syndrome

| At least two of | WHO* | NCEP† | IDF‡ |
|----------------|------|-------|------|
| BMI            | ≥ 0.30 |       | ≥ 30 |
| Waist circumference (cm) | ≥ 94 | > 102 | ≥ 94 |
| Waist hip ratio | > 0.90 |       | > 0.90 |
| Triglycerides (mg/dl) | ≥ 150 | ≥ 150 | ≥ 150 |
| HDL-cholesterol (mg/dl) | < 35 | < 40 | < 35 |
| Blood pressure (mmHg) | ≥ 140/90 or medication | ≥ 130/85 or medication | ≥ 140/90 or medication |
| Fasting glucose (mg/dl) | ≥ 110 | ≥ 110 | |
| Fasting insulin | Upper quartile of non-diabetic | | Insulin resistance |

*World Health Organization, Diabetes Med 1999; 16: 442–3. †National Cholesterol Education Program, JAMA 2001; 285: 2486–97. ‡International Diabetes, J Urol 2005; 174: 827–34. BMI, body mass index; HDL, high-density lipoprotein.
A recent systematic review and meta-analysis of cross-sectional studies indicated that testosterone level was significantly lower in men with type 2 diabetes mellitus compared with men without a history of diabetes, even without adiposity (24).

**Metabolic effects of (rather) acute androgen deprivation in men with prostate cancer**

Prostate cancer is an androgen-dependent malignancy and, consequently, androgen deprivation treatment (ADT) has a role to play in its management (38). Several studies have documented the deterioration of metabolic control upon ADT (39–49) in diabetic and non-diabetic men. Collectively, these studies have found that ADT leads to an increase in fat mass, an increase in plasma insulin, decreased insulin sensitivity (48), increased levels of glycosylated haemoglobin, an increase in plasma cholesterol, LDL-cholesterol and triglycerides but also an increase in plasma HDL-cholesterol, which contrasts with the low HDL-cholesterol levels found in the metabolic syndrome.

A recent study analysed the effects of GnRH agonist administration to men with prostate cancer; 73,196 Medicare patients ≥ 66 years who had locoregional prostate cancer between 1992 and 1999 were followed through 2001. The study assessed whether treatment with GnRH agonists or was associated with diabetes, coronary heart disease, myocardial infarction and sudden cardiac death. GnRH agonist therapy was associated with increased risk of incident diabetes [adjusted hazard ratio (HR), 1.44; p < 0.001], coronary heart disease (adjusted HR, 1.16; p < 0.001), myocardial infarction (adjusted HR, 1.11; p = 0.03) and sudden cardiac death (adjusted HR, 1.16; p = 0.004). Therefore, GnRH agonist treatment should be weighed against these potential risks (44).

At the cellular levels there is now insight into the effects of androgen deprivation/administration on fat mass. Testosterone regulates lineage determination in mesenchymal pluripotent cells by promoting their commitment to the myogenic lineage and inhibiting their differentiation into the adipogenic lineage through an androgen receptor-mediated pathway. The observation that differentiation of pluripotent cells is androgen dependent provides a unifying explanation for the reciprocal effects of androgens on muscle and fat mass in men (50,51).

Prostate cancer patients treated with ADT need to be monitored with reference to possible metabolic consequences of ADT. The survival of patients with prostate cancer has improved considerably. Cause of death in prostate cancer patients is no longer mainly because of the malignancy but to other conditions (52). Therefore, it has become increasingly important to address side effects of treatment timely and appropriately (53).
diabetes [mean difference, −76.6 ng/dl; 95% confidence interval (CI), −99.4 to −53.6]. Similarly, prospective studies showed that men with higher testosterone levels (range: 449.6–605.2 ng/dl) had a 42% lower risk of type 2 diabetes (relative risk, 0.58; 95% CI: 0.39–0.87). In addition, several large prospective studies have shown that low testosterone levels predict development of type 2 diabetes in men (22,23,55).

A recent study analysing the effects of testosterone administration to 24 hypogonadal men (10 treated with insulin) over the age of 30 years with type 2 diabetes found that testosterone replacement therapy reduced insulin resistance (as measured by homeostatic model index) and improved glycaemic control in hypogonadal men with type 2 diabetes (56). There are indications now that the beneficial effects of testosterone on the metabolic syndrome are related to their impact on body composition and this effect will only occur in the longer-term (57,58) 6–12 months of testosterone administration. This might explain why shorter term studies (3 months) do not show many favourable effects (56).

New insights into the relationship of androgens and erectile dysfunction

Erectile response in mammals is centrally and peripherally regulated by androgens. Severe hypogonadism in men usually results in loss of libido and potency which can be restored by androgen administration. The original insights into the mechanisms of action of androgens on sexual function indicated a prominent role of testosterone on sexual interest while the effects of testosterone on erectile function were less apparent from these investigations (59). There is growing insight that testosterone has profound effects on tissues of the penis involved in the mechanism of erection and that testosterone deficiency impairs the anatomical and physiological/biochemical substrate of erectile capacity, reversible upon androgen treatment. An improvement of nocturnal erections [tumescence and rigidity, spontaneous and sexually related erections was found in men with androgen deficiency upon treatment with transdermal testosterone (60) and eugonadal circumstances].

Several studies have indicated that the administration of phosphodiesterase inhibitor type-5 (PDE-5) inhibitors is not always sufficient to restore erectile potency in men, and that administration of testosterone improves the therapeutic response to PDE-5 inhibitors considerably (61,62). There is increasing insight not to view ED as a single entity but as part of the ageing process. Circulating levels of testosterone are closely related to manifestations of other aetiological factors in ED, such as atherosclerotic disease and diabetes mellitus. The latter are correlated with lower-than-normal testosterone levels.

Erectile difficulties provide often a window into the presence of pathology in these areas. Rather than a disease in itself, ED is, particularly in elderly men who have enjoyed normal sexual function earlier in life, a manifestation of pathologies of the biological systems involved in erectile function (63).

Animal experiments and, to a much more limited degree, human observations suggest that androgens are necessary to maintain the integrity of the anatomical structures of the penile erectile tissue and, further, that androgens are significant in the biochemical mechanisms subserving penile erection.

There is now ample evidence from animal studies that androgen deprivation produces changes in the histological properties of penile structures. Schabsigh (64) could demonstrate that castration caused apoptosis in the rat corpus cavernosum smooth muscle after only 3 days. Administration of testosterone restored DNA synthesis already after 4 days. In a rat model Shen et al. [reviewed in (65)] demonstrated that androgen deprivation leads to loss of elastic fibres in the tunica albuginea and of smooth muscle fibres in the corpus cavernosum [reviewed in (65)] which were replaced by collagenous fibres in both structures. Singh et al. [reviewed in (65)] found that the mesenchymal pluripotent cells follow a myogenic lineage or adipogenic lineage depending on circulating levels of testosterone, confirmed by Traish et al. [reviewed in (65)].

Traish and coworkers [reviewed in (65)] demonstrated that even a 50% reduction in circulating testosterone reduced intracavernosal blood pressure which was not enhanced by administration of the PDE-5 inhibitor vardenafil. Zhang et al. (66) showed that also continuous administration of tadalafil could not enhance erectile response in castrated animals. Nitric oxide synthase and arginase activities in the corpus cavernosum were not significantly affected by the reduction in circulating testosterone confirmed in human tissue by Morelli et al. (67). Yassin and Saad (68) showed that adequate testosterone treatment can restore venous leakage in the corpus cavernosum which is a frequent etiological factor in ED in elderly men.

Schiavi and Rehman (69), based on their clinical experience, hypothesised that the threshold for the biological actions of testosterone might be higher in elderly men compared with young men. Their hypothesis was recently convincingly experimentally confirmed by Gray et al. (70) showing that, compared with younger men, elderly men require higher
levels of circulating testosterone for libido and erectile function.

**Erectile dysfunction is a ‘portal’ to men’s health**

The above has demonstrated a close relationship between ailments frequently occurring in the ageing male (visceral obesity, cardiovascular disease, diabetes mellitus and ED) on the one hand and hypogonadism on the other. In view of this close relationship, late onset hypogonadism is probably an expression of poor health with a high-risk profile for debilitating diseases, as may be concluded from a recent study. Low testosterone levels were associated with increased mortality in male veterans (71). This association between sex steroids and all-cause and cause-specific mortality could not be confirmed in Massachusetts Male Aging Study (72).

Men usually are in denial of ailments at all ages, but certainly also when they are ageing. Erectile function is viewed by almost all men as a significant component of quality of life (73) and erectile difficulties (ED) may be a reason to seek medical advice. Several studies document now that there is a high concordance between the causes of ED and the causes of cardiovascular disease, this indirectly by demonstrating that there is an elevated prevalence of the metabolic syndrome and insulin resistance in a population of men with ED when compared with a general population of men (74). The authors argue that the ultimate goal therefore must be not only to treat the erectile problem but also to diagnose and adequately (aggressively) treat any cardiac risk factors that may be found.

The prestigious Massachusetts Male Aging Study equally revealed that ED was predictive of the metabolic syndrome, although only in men with BMI < 25. This finding also supports the notion that waist circumference or waist/hip ratio are more reliable indicators of the metabolic syndrome that BMI. This study supports the idea that ED may provide a warning sign and, at the same time, an opportunity for early intervention in men otherwise considered at high risk for the metabolic syndrome and subclinical mortality (75). The Massachusetts Male Aging Study (MMAS) has estimated the frequency of ED progression and remission among ageing men, and assessed the relation of progression/remission to demographics, socioeconomic factors, comorbidities and modifiable lifestyle characteristics. Natural remission and progression occur in a substantial number of men with ED. Age and BMI were associated with progression and remission of ED. Interventions were non-pharmaco-

| Variable          | Answer | Values | Score |
|------------------|--------|--------|-------|
| Health status    | 0.5    |        |       |
| Severe ED        | 1      |        |       |
| Sexual partner   | −1.5   |        |       |
| Waist size: 86–91 cm | 1  |        |       |
| Waist size: 96–101 cm | 2  |        |       |
| Waist size over 106 cm | 2  |        |       |

Total

Y = f (health status, waist size, ED severity and sexual partner) where Y = 0, 1 (no disease/disease). 90% sample = 349. 10% holdout sample = 40. Risk for hypertension, diabetes, angina or hyperlipidaemia. Score ranges from 0 to 7.

- ≥ 2.5 = high risk (≥ 60% probability of having the condition).
- 1.5–2.5 = medium risk (30–59% probability).
- < 1.5 = low risk (< 30% probability).

Score of our patient: 3 = high risk.

If he had not had ED: 2 = medium risk.
This could be physiologically hypothesised as surrogate for vascular health. The third question is about having a good relationship with the partner. This could be hypothesised to be surrogate for mental and behavioural health. The fourth question is about waist circumference, which can be hypothesised to be a surrogate for metabolic health. Elements in the calculation of health risks (hypertension, diabetes, angina or hyperlipidaemia) in men presenting with ED are: health status on a scale of 1–7 (1 = excellent, 7 = poor), waist circumference, severity of ED, presence/absence of a sexual partner. The calculation produces scores of ranges of 1–7. If the score is 1.5–2.5 = medium risk (30–59% probability); ≥ 2.5 = high risk (≥ 60% probability of having the condition) and < 1.5 = low risk (< 30% probability).

Conclusions

Sexual health may be the portal to men’s health. Lifestyle changes involving more exercise and a lower caloric intake, with a Mediterranean type of diet, appear to improve sexual function (77,78). It is recommended that these measures are lifelong.

Hypogonadism and ED are epidemiologically associated with and may predict metabolic syndrome and diabetes type 2. However, there are significant limitations and knowledge gaps. Most evidence of the link of hypogonadism and metabolic syndrome is observational. Interventional studies are needed to determine the relationship between testosterone and diabetes mellitus and the metabolic syndrome to assess the benefit/risk ratio of testosterone replacement therapy in men with the hypogonadism, diabetes and the metabolic syndrome. Treatment of ED may entail testosterone administration (80) and these interventional studies may provide an opportunity to determine therapeutic and preventive feasibility, benefits and justification of testosterone administration on the closely interrelated ailments of ED and the metabolic syndrome of which epidemiologically hypogonadism is a correlate.

References

1 Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003; 24: 313–40.
2 Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003; 24: 183–217.
3 Jones RD, Nettleship JE, Kapoor D et al. Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiavasc Drugs 2005; 5: 141–54.
4 Hak AE, Witteman JC, de Jong FH et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 2002; 87: 3632–9.
5 Svarberg J. Epidemiology: testosterone and the metabolic syndrome. Int J Impot Res 2007; 19: 124–8.
6 Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997; 82: 3793–6.
7 Shahriagh R, Katz M, Yan G, Makkhsida N. Cardiovascular issues in hypogonadism and testosterone therapy. Am J Cardiol 2005; 96: 67M–72M.
8 English KM, Steeds RP, Jones TH et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000; 102: 1906–11.
9 Malkin CJ, Pugh PJ, West JN et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006; 27: 57–64.
10 Ogden CL, Carroll MD, Flegal KM. Epidemiologic trends in overweight and obesity. Endocr Metab Clin North Am 2003; 32: 741–60.
11 Bjorntorp P, Rosmond R. The metabolic syndrome – a neuroendocrine disorder? Br J Nutr 2000; 83 (Suppl. 1): S49–57.
12 Grundy SM, Brewer HB Jr, Cleeman JI et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004; 24: e13–8.
13 Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 2004; 89: 2601–7.
14 Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2799–16.
15 Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28: 2745–9.
16 Shiwaku K, Anuarud E, Enkmaa B et al. Predictive values of anthropometric measurements for multiple metabolic disorders in Asian populations. Diabetes Res Clin Pract 2005; 69: 52–62.
17 Hu G, Qiao Q, Tuomilehto J et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066–76.
18 Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414–9.
19 Kalme T, Seppala M, Qiao Q et al. Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. J Clin Endocrinol Metab 2005; 90: 1550–60.
20 Kupelian V, Page ST, Araujo AB et al. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 91: 843–50.
21 Laaksonen DE, Niskanen L, Punnonen K et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036–41.
22 Oh YI, Barrett-Conner E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002; 25: 55–60.
23 Stellato RK, Feldman HA, Hamdy O et al. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000; 23: 490–4.
24 Selvin E, Feinleib M, Zhang L et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007; 30: 234–8.
25 Muller M, Grobbee DE, den Tonkelaar I et al. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005; 90: 2618–23.
26 Tibblin G, Adlerberth A, Lindstedt G, Björntorp P. The pituitary-gonadal axis and health in elderly men: a study of men born in 1913. Diabetes 1996; 45: 1605–9.

27 Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005; 63: 239–50.

28 Makhsood N, Shah J, Yan G et al. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 2005; 174: 827–34.

29 Yesilova Z, Oktel CH, Sanisoglu SY et al. Evaluation of insulin sensitivity in patients with Klinefelter’s syndrome: a hyperinsulinemic euglycemic clamp study. Endocrine 2005; 27: 11–5.

30 Pitteloud N, Mootha VK, Dwyer AA et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005; 28: 1636–42.

31 Isidori AM, Caprio M, Strollo F et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 1999; 84: 3673–80.

32 Caprio M, Isidori AM, Carta AR et al. Expression of functional leptin receptors in rodent Leydig cells. Endocrinology 1999; 140: 4293–47.

33 Soderberg S, Olsson T, Eilasson M et al. A strong association between bioactively active testosterone and leptin in non-obese men and women is lost with increasing (central) adiposity. Int J Obes Relat Metab Disord 2001; 25: 98–105.

34 Van Den Saffele JK, Goemaere S, De Bacqer D, Kaufman JM. Changes in fat and lean body mass during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2006; 91: 1305–8.

35 Pitteloud N, Hardin M, Dwyer AA et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005; 90: 2636–41.

36 Lima N, Cavaliere H, Knoebel M et al. Decreased androgen levels in massively obese men may be associated with impaired function of the gonadostat. Int J Obes Relat Metab Disord 2000; 24: 1433–7.

37 Vermeulen A, Kaufman JM, Deslypere JP, Thomas G. Attempted luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab 1993; 76: 1140–6.

38 Labrie F, Belanger A, Luu-The V et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 2005; 26: 361–79.

39 Inaba M, Otani Y, Nishimura K et al. Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment. Metabolism 2005; 54: 55–9.

40 Basaria S, Lieb J 2nd, Tang AM et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002; 56: 779–86.

41 Basaria S, Muller DC, Carducci MA et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006; 106: 581–8.

42 Braga-Basaria M, Dobs AS, Muller DC et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24: 5973–83.

43 Braga-Basaria M, Muller DC, Carducci MA et al. Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res 2006; 18: 494–8.

44 Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 27: 4448–56.

45 Smith MR. Changes in body composition during hormonal therapy for prostate cancer. Clin Prostate Cancer 2003; 2: 18–21.

46 Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004; 63: 742–5.

47 Smith MR, Finkelstein JS, McGovern FJ et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599–603.

48 Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91: 1305–8.

49 Yannucci J, Manola J, Garnick MB et al. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol 2006; 176: 520–5.

50 Singh AB, Hsa S, Aluapovic P et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 2002; 87: 136–43.

51 Singh R, Artaza JN, Taylor WE et al. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells; nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 2006; 147: 141–54.

52 Lu-Yao G, Stukel TA, Yao SL. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol 2004; 170: 2285–90.

53 Moyad MA. Promoting general health during androgen deprivation therapy. Urol Clin North Am 2006; 33: 551–6.

54 Kapoor D, Aldred H, Clark S et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007; 30: 911–7.

55 Tomar R, Dhindsa S, Chaudhuri A et al. Contrasting testosterone concentrations in type 1 and type 2 diabetes. Diabetes Care 2006; 29: 1120–2.

56 Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899–906.

57 Boyanov MA, Boneva Z, Chrestov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003; 6: 1–7.

58 Marin P, Holmang S, Gustafsson C et al. Androgen treatment of abdominally obese men. Obes Res 1993; 1: 245–51.

59 Bancroft J, Wu FC. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav 1983; 12: 59–66.

60 Arver S, Dobs AS, Meikle AW et al. Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J Urol 1996; 155: 1604–8.

61 Aversa A, Isidori AM, Spera G et al. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003; 58: 632–8.

62 Greco EA, Spera G, Aversa A. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. Eur Urol 2006; 50: 940–7.

63 Shabsigh R, Perlman MA, Lockhart DC et al. Health issues of men: prevalence and correlates of erectile dysfunction. J Urol 2005; 174: 662–7.

64 Shabsigh R. The effects of testosterone on the cavernous tissue and erectile function. World J Urol 1997; 15: 21–6.

65 Goozen LJ, Saad F. Recent insights into androgen action on the anatomical and physiological substrate of penile erection. Asian J Androl 2006; 8: 3–9.

66 Zhang XM, Morelli A, Luconi M et al. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol 2005; 47: 409–16; discussion 16.

67 Morelli A, Filippi S, Mancina R et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004; 145: 2253–63.

68 Yassin AA, Saad F. Dramatic improvement of penile venous leakage upon testosterone administration. A case report and review of literature. Andrology 2006; 38: 34–7.

69 Schiavi RC, Rehman J. Sexuality and aging. Urol Clin North Am 1995; 22: 711–26.
70 Gray PB, Singh AB, Woodhouse LJ et al. Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab 2005; 90: 3838–46.
71 Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166: 1660–5.
72 Araujo A, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, McKinlay JB. Sex steroids and all-cause mortality and cause-specific mortality in men. Arch Intern Med 2007; 167: 1252–60.
73 Holden CA, McLachlan RI, Pitts M et al. Men in Australia Telephone Survey (MATEs): a national survey of the reproductive health and concerns of middle-aged and older Australian men. Lancet 2005; 366: 218–24.
74 Bansal TC, Guay AT, Jacobson J et al. Incidence of metabolic syndrome and insulin resistance in a population with organic erectile dysfunction. J Sex Med 2005; 2: 96–103.
75 Kupelian V, Shabsigh R, Araujo AB et al. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol 2006; 176: 222–6.
76 Travison TG, Shabsigh R, Araujo AB et al. The natural progression and remission of erectile dysfunction: results from the Massachusetts Male Aging Study. J Urol 2007; 177: 241–6; discussion 6.
77 Esposito K, Giugliano F, Di Palo C et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004; 291: 2978–84.
78 Esposito K, Marfella R, Ciottola M et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004; 292: 1440–6.
79 Shabsigh R, Rajfer J, Aversa A et al. The evolving role of testosterone in the treatment of erectile dysfunction. Int J Clin Pract 2006; 60: 1087–92.
80 Traish AM, Guay AT. Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med 2006; 3: 582–404; discussion.

Paper received September 2007, accepted November 2007